Dr. Mahsa Tehrani discusses how patients use medication to help them lose weight on 'America Reports.' ...

A drug that can be taken orally could soon rival the likes of Ozempic for treating type 2 diabetes and obesity, according to a new study.

Patients taking semaglutide, the active ingredient in Ozempic, were less likely to develop Alzheimer’s. Randomized clinical trials are needed to pin down the exact cause of this difference in risk.

The Ethicist Is It Wrong to Push Ozempic on My Spouse? He’s very sensitive about his weight.

A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials. Drugs like Wegovy and Mounjaro – or diabetes jab Ozem… ...

A new oral drug may be able to treat type 2 diabetes and obesity without impacting muscle mass as an alternative to GLP-1 drugs such as Ozempic, the results of a phase 1 clinical trial suggest.

People with type 2 diabetes who used semaglutide (Ozempic) versus other drugs had a lower risk of Alzheimer's disease and related dementia, especially vascular dementia, electronic health records ...

CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.

Ozempic Might Be a Dementia Buster, Too Research out today is the latest to suggest that semaglutide can significantly lower people's risk of dementia. By Ed Cara Published June 24, 2025 ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.